New hope for advanced head and neck cancer: drug combo trial launches

NCT ID NCT07062354

ENROLLING_BY_INVITATION Disease control Sponsor: SWOG Cancer Research Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study tests a combination of the targeted drug amivantamab plus two chemotherapy drugs (carboplatin and paclitaxel) in 50 people with head and neck cancer that has come back or spread. The goal is to see if this treatment shrinks tumors or controls the disease. Participants must have already tried a PD-1 inhibitor and not received platinum chemo before.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD &AMP; NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD &AMP; NECK CANCER HEAD &AMP; NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Medical Univ of South Carolina

Charleston, South Carolina, 29425, United States
UC Irvine Medical Center

Orange, California, 92868, United States
UCI Health - Chao Family CCC & Ambulatory Care

Irvine, California, 92612, United States
University of Arizona Cancer Center

Tucson, Arizona, 85719, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.